S. Black

发表

Experimental Models for the Assessment of Antiarrhythmic and Proarrhythmic Drug Action: Traditional and Newer Models

B. Lucchesi, G. Friedrichs, S. Black, 1995 .

UK-68,798, a class III antiarrhythmic drug with antifibrillatory properties

B. Lucchesi, S. Black, 1992 .

Methods for studying experimental myocardial ischemic and reperfusion injury.

I. Rodger, S. Black, 1996, Journal of pharmacological and toxicological methods.

Beneficial Metabolic Effects of CB1R Anti-Sense Oligonucleotide Treatment in Diet-Induced Obese AKR/J Mice

K. Demarest, Yin Liang, Yuting Tang, 2012, PloS one.

Heat Shock Proteins and the Ischemic Heart An Endogenous Protective Mechanism

B. Lucchesi, S. Black, 1993, Circulation.

Omega-3 fatty acid treatment fails to alter α1-adrenergic receptor mediated phosphoinositide turnover in streptozotocin-induced diabetic rats

J. McNeill, S. Black, S. Katz, 1990 .

Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice.

S. Black, A. L. Hildebrandt, D. Kelly-Sullivan, 2003, European journal of pharmacology.

Antiarrhythmic versus antifibrillatory actions: inference from experimental studies.

L. Chi, A. Uprichard, B. Lucchesi, 1993, The American journal of cardiology.

Co-localization of the cysteine protease caspase-3 with apoptotic myocytes after in vivo myocardial ischemia and reperfusion in the rat.

S. Radinovic, D. Nicholson, A. Eberhart, 1998, Journal of molecular and cellular cardiology.

Antifibrillatory effects of ibutilide in the rabbit isolated heart: mediation via ATP-dependent potassium channels.

J. Oh, L. Chi, B. Lucchesi, 1993, Journal of Pharmacology and Experimental Therapeutics.

In vivo models of myocardial ischemia and reperfusion injury: application to drug discovery and evaluation.

S. Black, 2000, Journal of pharmacological and toxicological methods.

Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.

M. Macielag, Yin Liang, Yuting Tang, 2016, Bioorganic & Medicinal Chemistry Letters.

Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists.

P. Connolly, M. Macielag, Yin Liang, 2016, Bioorganic & medicinal chemistry letters.

Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury.

S. Black, J. MacAndrew, S. Ellery, 2001, European journal of pharmacology.

Pharmacological characterization of a small molecule inhibitor of c-Jun kinase.

Ping Chen, K. Ogilvie, Sergei L Timofeevski, 2008, American Journal of Physiology. Endocrinology and Metabolism.

Influence of omega-3 fatty acid treatment on cardiac phospholipid composition and coronary flow of streptozocin-diabetic rats.

J. McNeill, S. Black, S. Katz, 1993, Metabolism: clinical and experimental.

In vivo myocardial infarct size reduction by a caspase inhibitor administered after the onset of ischemia.

S. Radinovic, J. Q. Huang, P. Rezaiefar, 2000, European journal of pharmacology.

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

D. Scott, D. Hargrove, R. L. Dow, 2010, Biochemical and biophysical research communications.

New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

D. Scott, P. Iredale, S. Sakya, 2006, Bioorganic & medicinal chemistry letters.

Phorbol ester-induced ventricular fibrillation in the Langendorff-perfused rabbit heart: antagonism by staurosporine and glibenclamide.

L. Chi, B. Lucchesi, G. Friedrichs, 1993, Journal of Molecular and Cellular Cardiology.

5-hydroxydecanoate fails to attenuate ventricular fibrillation in a conscious canine model of sudden cardiac death.

L. Chi, B. Lucchesi, G. Friedrichs, 1996, European Journal of Pharmacology.

Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury.

B. Lucchesi, G. Friedrichs, K. Kilgore, 1995, Cardiovascular research.

Validation of a high-resolution X-ray computed tomography system to measure murine adipose tissue depot mass in situ and longitudinally.

S. Black, A. L. Hildebrandt, D. Kelly-Sullivan, 2002, Journal of pharmacological and toxicological methods.

Protection Against Programmed Electrical Stimulation-Induced Ventricular Tachycardia and Sudden Cardiac Death by NE-10064, a Class III Antiarrhythmic Drug

B. Lucchesi, S. Black, J. L. Butterfield, 1993, Journal of cardiovascular pharmacology.

Effect of ranolazine on infarct size in a canine model of regional myocardial ischemia/reperfusion.

J. Mccormack, B. Lucchesi, M. Gralinski, 1994, Journal of cardiovascular pharmacology.

Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart.

J. Mccormack, B. Lucchesi, K. Kilgore, 1994, Cardiovascular research.

Sarcoplasmic reticulum Ca2+ transport and long chain acylcarnitines in hyperthyroidism.

J. McNeill, S. Black, S. Katz, 1988, Canadian journal of physiology and pharmacology.

Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

D. Scott, P. Iredale, Xingrong Liu, 2010, BMC pharmacology.

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity.

D. Scott, P. Iredale, C. Nduaka, 2009, Journal of medicinal chemistry.

Cardiac Performance and Plasma Lipids of Omega-3 Fatty Acid–Treated Streptozocin-Induced Diabetic Rats

J. McNeill, S. Black, S. Katz, 1989, Diabetes.

Molecular and Subcellular Mechanisms of Thyroid Hormone Induced Cardiac Alterations

J. McNeill, S. Black, 1990 .

Thyroidectomy of SHR: effects on ventricular relaxation and on SR calcium uptake activity.

J. McNeill, S. Black, S. Katz, 1986, American Journal of Physiology.

Inhibition of in vivo myocardial ischemic and reperfusion injury by a synthetic manganese-based superoxide dismutase mimetic.

B. Lucchesi, D. Riley, C. Schasteen, 1994, The Journal of pharmacology and experimental therapeutics.

Inhibition of coronary artery reocclusion after thrombolysis with an RGD‐containing peptide with no significant effect on bleeding time

B. Lucchesi, M. Pierschbacher, E. Driscoll, 1993, Coronary artery disease.

Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta.

J. Stock, J. Mcneish, K. Coleman, 2003, The Journal of clinical investigation.

Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex

M. Hayden, S. Hadano, B. Koop, 1998, Cell Death and Differentiation.

Calcium transport activity of rat cardiac sarcoplasmic reticulum isolated in the presence of dithiothreitol.

J. McNeill, S. Black, S. Katz, 1991, Journal of pharmacological methods.

Effect of Ramiprilat or Captopril on Myocardial Infarct Size: Assessment in Canine Models of Ischemia Alone and Ischemia with Reperfusion

B. Lucchesi, E. Driscoll, S. Black, 1998, Pharmacology.

The antifibrillatory actions of UK-68,798, a class III antiarrhythmic agent.

L. Chi, B. Lucchesi, D. Mu, 1991, The Journal of pharmacology and experimental therapeutics.

Selective Matrix Metalloproteinase Inhibition Reduces Left Ventricular Remodeling but Does Not Inhibit Angiogenesis After Myocardial Infarction

Richard T. Lee, P. Libby, M. Lindsey, 2002, Circulation.

Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Margaret S. Landis, D. Scott, P. Iredale, 2009, Journal of medicinal chemistry.

Inhibition of Platelet-Activating Factor Fails to Limit Ischemia and Reperfusion-Induced Myocardial Damage

B. Lucchesi, E. Driscoll, S. Black, 1992, Journal of cardiovascular pharmacology.

Cardiac sarcoplasmic reticulum calcium transport activity of thyroidectomized rats: the role of endogenous myocardial acylcarnitines and calcium pump protein.

J. McNeill, S. Black, S. Katz, 1993, Pharmacology.

Cannabinoid receptor antagonists and obesity.

S. Black, 2004, Current opinion in investigational drugs.

Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs.

C. Brideau, C. Chan, I. Rodger, 1998, Journal of cardiovascular pharmacology.

Potassium channel openers are likely to be proarrhythmic in the diseased human heart.

B. Lucchesi, S. Black, 1994, Cardiovascular research.

Centrally Acting Anti-Obesity Agents

D. Hepworth, S. Black, P. Carpino, 2006 .

MS‐551 Protects Against Ventricular Fibrillation in a Chronic Canine Model of Sudden Cardiac Death

L. Chi, B. Lucchesi, G. Friedrichs, 1995, Journal of cardiovascular pharmacology.

The autonomic nervous system, myocardial infarct size and ventricular fibrillation.

B. Lucchesi, G. Friedrichs, S. Black, 1993, Journal of molecular and cellular cardiology.

Comparison of pre‐clinical pharmacokinetic (PK) and pharmacodynamic (PD) relationships of cannabinoid CB1 receptor antagonists in a drug development program for weight loss (WL) management

D. Scott, J. Hadcock, S. Black, 2008 .

Antiarrhythmic Agent, MS‐551, Protects Against Pinacidil + Hypoxia‐Induced Ventricular Fibrillation in Langendorff‐Perfused Rabbit Isolated Heart

L. Chi, B. Lucchesi, G. Friedrichs, 1994, Journal of cardiovascular pharmacology.